Dishman Carbogen Amcis Ltd
Dishman Carbogen Amcis Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025). Revenue and profitability are expected to keep increasing overall, though no specific quarterly guidance is provided due to business nature.
From Dishman Carbogen Amcis Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025).
- Full-year revenue and profitability expected to increase compared to the previous year; Q2 likely to pick up with integration efforts between Switzerland, India, and France facilities.
- France facility expects revenue growth to reduce current EBITDA losses over the year.
- HiPo facility in India (Bavla) is being evaluated for new projects; positive outlook for re-starting operations soon.
- Soft-gel business and CRAMS in India are expanding, with increasing commercial quantities and market interest in semi-regulated markets.
- Market focus on U.S., Europe, and Japan, with significant growth potential especially in Japan.
- No specific quarterly guidance given, but overall growth trajectory and mid- to long-term outlook is positive.
Profitability & Margins
See what Dishman Carbogen Amcis Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Co-investment in new facility in Switzerland with a large Japanese customer focused on ADC products.
- Japanese customer's investment: 15 million CHF initially; second round investment 25 million CHF, with Dishman contributing internal hours, not cash.
- Full-year CAPEX guidance reduced to below initial 25 million Swiss francs estimate; Q1 CAPEX was around US$5.6 million (~4 million CHF).
- Focus on expanding soft gel manufacturing in India (Bavla) targeting semi-regulated markets with growing commercial quantities.
- Efforts ongoing to restart and generate revenues from the HiPo facility in Bavla, India.
- Fundraise plans underway with an enabling resolution taken; main aim includes debt reduction to improve financial flexibility.
- Integration efforts among Switzerland, India, and France aiming to enhance capacity and profitability in upcoming quarters.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Dishman Carbogen Amcis Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- As of June 30, 2025:
- - Development pipeline: Approximately 117 million Swiss francs.
- - Commercial order book: Roughly 77 million Swiss francs (for Carbogen Amcis).
- The order book reflects ongoing healthy demand and robust pipeline for the company’s CDMO business.
- There is optimistic visibility on increased revenues driven by integration of Swiss, Indian, and French facilities, and ramp-up of the French facility and Swiss RFPs.
- No specific quarter-wise order book growth guidance is provided due to the business nature, but overall full-year revenue and profitability are expected to improve.
Dishman Carbogen Amcis Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹851 Cr, net profit ₹22 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Dishman Carbogen Amcis Ltd's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q4 FY25 earnings call analysis →
- Q4 FY26 earnings call analysis →
- Q2 FY26 earnings call →
- Q3 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
- Senores Pharmaceuticals Ltd (Q1 FY26)
. Key concall takeaways from Senores Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Dishman Carbogen Amcis Ltd Q1 FY26 results?
Development pipeline at approximately 117 million Swiss francs as of June 30, 2025; commercial order book around 77 million Swiss francs (Q2 2025). Revenue and profitability are expected to keep increasing overall, though no specific quarterly guidance is provided due to business nature.
What is Dishman Carbogen Amcis Ltd share price analysis?
Dishman Carbogen Amcis Ltd currently shows a neutral. The stock trades at a P/E of 164.8 with a market cap of ₹2,989 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dishman Carbogen Amcis Ltd planning capital expenditure?
Co-investment in new facility in Switzerland with a large Japanese customer focused on ADC products.
Keep Dishman Carbogen Amcis Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.